What is the market's earnings forecast for Dexcom next quarter?

What guidance did Dexcom's management provide for the next earnings period?

What were the key takeaways from Dexcom’s earnings call?

Did Dexcom beat or miss consensus estimates last quarter?

What were the key takeaways from Dexcom's earnings call?

What is the revenue and EPS growth rate for Dexcom year over year?

What is Dexcom's latest dividend and current dividend yield?

What factors drove the changes in Dexcom's revenue and profit?

- **Revenue Growth**: Q4 2025 up 13% to $1.26 billion, with 2026 guidance of 11-13% growth.
- **Product Innovation**: G7 15 Day launched globally, improving accuracy and wear time.
- **Strategic Expansion**: Targeting 12 million Medicare beneficiaries for type 2 non-insulin coverage, with 2026 RCT data.
- **Financial Strength**: $2 billion cash, 2025 free cash flow >$1 billion, and 2026 gross margin 63-64%.
- **International Ambition**: Ireland manufacturing to support global expansion, with Europe/Asia-Pacific growth targeting 15-18%.

**【CEO Summary Section】**
- DexCom reported Q4 2025 revenue of $1.26 billion, up 13% year-over-year, driven by strong demand in the U.S. and international markets.
- Launched G7 15 Day sensor in early 2026, achieving 15-day wear time with improved accuracy and algorithm enhancements.
- Strategic priorities include expanding CGM access for type 2 non-insulin users, enhancing customer experience through AI-driven features, and international market expansion.
- 2025 full-year revenue exceeded high-end guidance, with Q4 gross margin improving to 63.5% due to supply chain efficiency.

**【CFO Financial Commentary】**
- Q4 2025 non-GAAP EPS was $0.68, with adjusted EBITDA of $422.2 million (33.5% of revenue).
- 2026 guidance: Revenue $5.16-5.25 billion (11-13% growth), gross margin 63-64%, operating margin 22-23%.
- Ireland manufacturing facility to begin production in Q4 2026, supporting long-term growth.
- Free cash flow exceeded $1 billion in 2025, with $2 billion in cash for strategic initiatives.

**【Q&A Key Highlights】**
- **CMS Coverage for Type 2 Non-Insulin Users**: DexCom expects CMS coverage decision in 2026, with RCT data release mid-2026. Potential 12 million Medicare beneficiaries could gain access.
- **International Growth**: Targeting 15-18% annual revenue growth in Europe and APAC, with G7 15 Day launching globally. France and Germany show strong type 2 coverage expansion.
- **Utilization Rates**: Type 2 non-insulin users in U.S. registry show 80-85% sensor utilization, comparable to basal insulin users.
- **G7 15 Day Impact**: Sensor deployment issues resolved, with Q4 2025 gross margin up 200+ basis points. Ireland facility will reduce freight costs and improve efficiency.
- **Stelo Contribution**: 2025 revenue $130 million, expected to contribute 1% to 2026 growth. New app features macronutrient tracking and meal logging.

DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript

**Key Takeaways:**
- **Revenue Growth Accelerates**: Q3 revenue up 22% YoY, driven by U.S. and international expansion into T2D markets.
- **15-Day Sensor Launch**: Limited U.S. rollout underway, with broader launch expected to drive 2026 growth.
- **Profitability Holds**: Adjusted EBITDA margin of 30.5% despite supply chain challenges, with free cash flow of $400 million.
- **2026 Guidance**: Base case for low double-digit revenue growth, with upside from potential T2D coverage expansion.

**【CEO Summary Section】**
- Reported third-quarter revenue of $1.21 billion, up 22% year-over-year, driven by 21% organic growth in the U.S. and 18% in international markets.
- Highlighted expansion of CGM coverage into non-insulin-dependent type 2 diabetes (T2D) populations, with 6 million U.S. commercial lives now covered.
- Announced the limited launch of a 15-day sensor in the U.S., with broader rollout expected in coming weeks, and a new digital experience for customers.
- Emphasized quality improvements in G7 sensors, with complaint rates stabilizing and scrap rates improving sequentially.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $368 million (30.5% of revenue), up 22% year-over-year.
- Gross margin of 61.3%, impacted by higher scrap rates and supply chain costs, but improving sequentially.
- Free cash flow of $400 million, with $3.3 billion in cash and equivalents.
- Raised 2025 revenue guidance to $4.63–$4.65 billion (15% growth) and adjusted EBITDA to $1.3–$1.35 billion.

**【Q&A Highlights】**
- **2026 Outlook**: Base case assumes no new coverage beyond current levels, with 15-day sensor contributing modestly to growth. Management expects low double-digit revenue growth and margin expansion.
- **Product Quality**: G7 scrap rates improving, with 15-day sensor launch proceeding as planned. No material impact on new patient starts expected.
- **Coverage Expansion**: Focused on securing CMS coverage for T2D, with potential impact on 2026 results if achieved.
- **Competitive Dynamics**: Multi-analyte platforms (e.g., Abbott's dual analyte) considered in base case, but DexCom's ecosystem and innovation pipeline seen as competitive advantages.

DexCom, Inc. (DXCM) Q3 2025 Earnings Call Transcript

- **Revenue Beat**: 15% organic growth driven by U.S. expansion and type 2 access wins. Q2 revenue $1.16 billion, up 15% YoY.
- **Innovative Products**: Stelo app downloads surpass 400,000; 15-day G7 system FDA-cleared for Q3 launch. AI features like Smart Food Logging enhance user experience.
- **Clinical Impact**: 40 ADA studies highlight CGM benefits in gestational diabetes and chronic kidney disease. RCTs on type 2 non-insulin care expected in 2026.
- **Financial Strength**: $2.9 billion cash; raised 2025 revenue guidance to $4.6 billion-$4.625 billion. Reaffirmed 62% gross margin target.
- **Strategic Focus**: Transition to Jake Leach as CEO; CMS competitive bidding risk mitigation; G8 development for multi-analyte sensing.

**【CEO Summary Section】**
- **Revenue Growth**: 15% organic revenue growth driven by U.S. market expansion and new access wins for type 2 non-insulin patients. U.S. revenue increased 15% to $841 million.
- **Product Launches**: Launched Stelo (over-the-counter glucose biosensor) with 400,000+ app downloads, integrating with Oura Ring for broader health data. Introduced 15-day G7 system with FDA clearance, targeting Q3 launch.
- **AI Integration**: Added Smart Food Logging feature for meal tracking and glycemic impact analysis. Enhanced data visualization and customizable target ranges for users.
- **Clinical Momentum**: Presented 40 studies at ADA, including RCTs on CGM for gestational diabetes and type 2 non-insulin care. Data showed DexCom CGM reduces chronic kidney disease progression.
- **CEO Transition**: Kevin Sayer to transition to Executive Chairman in 2026, with Jake Leach becoming President and CEO. Emphasized continuity and strategic focus on access and innovation.

**【CFO Financial Commentary】**
- **Revenue**: Q2 2025 revenue $1.16 billion (15% YoY growth). U.S. revenue $841 million (15% YoY), international revenue $316 million (16% YoY).
- **Margins**: Gross profit $695.9 million (60.1% of revenue). Operating income $221.8 million (19.2% of revenue). Adjusted EBITDA $327.6 million (28.3% of revenue).
- **Cash Position**: $2.9 billion in cash, supporting strategic initiatives and capital allocation flexibility.
- **Guidance Update**: Raised full-year revenue guidance to $4.6 billion-$4.625 billion (14%-15% growth). Reaffirmed 2025 targets: 62% gross margin, 21% operating margin, 30% EBITDA margin.
- **Cost Management**: Invested in expedited shipping to rebuild inventory, impacting gross margin but ensuring customer supply.

**【Q&A Highlights】**
- **CMS Competitive Bidding**: 15% of business exposed to Medicare competitive bidding. DexCom focuses on value proposition and uninterrupted access for patients. Potential 2027 implementation.
- **G8 Development**: G8 sensor 50% smaller, with multi-analyte sensing capability. Development focused on safety, reliability, and ease of use. Launch timing TBD post-clinical studies.
- **Stelo Adoption**: Stelo app downloads exceed 400,000, targeting 2%-3% of sales in 2025. Primary users: prediabetes, type 2 non-insulin, and wellness markets.
- **Margin Progression**: Expect sequential margin improvement in Q3 and Q4, targeting 62% gross margin for the year. Recall-related costs (~100bps) in Q2.
- **International Growth**: Accelerated growth in DexCom ONE+ platform, with Ontario Drug Benefit Program expansion in Canada. Focus on basal insulin coverage in Europe and emerging markets.


DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript

- **Record Growth**: 14% organic revenue growth, driven by new customer starts (+15% U.S.) and Stelo adoption (>200,000 downloads).
- **Payer Expansion**: 3 PBMs now cover Dexcom G7 for all diabetes patients, targeting 6M type 2 non-insulin users by year-end.
- **Product Innovation**: FDA-cleared 15-Day G7 System set for Q2 launch; Stelo features integrating into G7 app.
- **Financial Resilience**: Maintained $4.6B revenue guidance despite 62% gross margin target, supported by $2.7B cash and $750M buyback.
- **Operational Challenges**: 57.5% Q1 gross margin due to supply costs; ongoing freight expenses (~100bps/year). FDA warning letter resolved without business impact.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 organic revenue increased 14% YoY, driven by strong demand in the U.S. and international markets. New customer starts reached a record high, with notable growth from the type 2 non-insulin population.
- **Product Launches**: Launched Stelo, the first OTC CGM, and the 15-Day Dexcom G7 System. Stelo saw strong adoption, with over 200,000 downloads, and the 15-Day sensor received FDA clearance for Q2 2025 launch.
- **Payer Expansion**: Secured coverage for Dexcom G7 for all people with diabetes at 3 major PBMs, expanding access to ~6 million type 2 non-insulin users by year-end. Launched a randomized controlled trial (RCT) for type 2 non-insulin patients.
- **Operational Challenges**: Navigated supply chain disruptions with expedited shipping, charter flights, and direct customer support. FDA issued a warning letter for manufacturing observations, but no impact on product distribution or innovation pipeline.

**【CFO Financial Commentary】**
- **Q1 2025 Results**: Revenue $1.036B (12% reported, 14% organic YoY). U.S. revenue grew 15% to $751M. Gross profit $596.2M (57.5% of revenue), down from 61.8% YoY due to supply chain costs. Operating expenses $453.1M (10% YoY increase). Net income $127.7M ($0.32 EPS).
- **Guidance Update**: Full-year 2025 revenue maintained at $4.6B. Reduced gross margin guidance to ~62% (from 63-64%) due to supply chain costs, inflation, and FX impacts. Operating and EBITDA margins reaffirmed at ~21% and 30%.
- **Share Repurchase**: Announced $750M share buyback program, reflecting confidence in cash flow and capital allocation.

**【Q&A Highlights】**
- **Supply Chain**: Channel inventory normalized by Q1 end, but internal inventory rebuilding required ongoing freight costs (~100bps margin impact). No manufacturing defects; focus on distribution efficiency.
- **International Growth**: Japan and France showed strength, but international growth (~7% YoY) lagged U.S. due to coverage delays. Expect coverage expansions in 2025 to drive future growth.
- **Gross Margin Trajectory**: Q1 gross margin at 57.5%, expected to improve sequentially with supply normalization. Full-year ~62% target includes 75bps impact from Q1 and ongoing cost pressures.
- **FDA Compliance**: Actively addressing warning letter observations with corrective actions. No impact on product approvals or launches.
- **Stelo Strategy**: Integrating Stelo features into G7 app to enhance value for type 2 non-insulin users. Amazon distribution expanded reach, with stelo.com still dominant.


DexCom (DXCM)-1 May 25-2025 Q1 Earnings call transcript

- **Record Q4 growth**: 8% organic revenue driven by U.S. prescriber expansion and international access wins.
- **Stelo momentum**: 140,000 users in 4 months, Amazon launch, and AI personalization to accelerate adoption.
- **Coverage expansion**: 2 PBMs now cover type 2 non-insulin, targeting 5 million U.S. lives by end-2025.
- **15-day sensor**: FDA approval imminent, with H2 2025 launch to drive 200+ basis points of gross margin improvement.
- **2025 guidance**: $4.6 billion revenue (14% growth), 64-65% gross margin, 21% operating margin.

**【CEO Summary Section】**
- Reported 8% organic revenue growth in Q4 2024, with full-year growth of 12% in line with guidance.
- Expanded U.S. prescriber base by 50,000, driving 25% increase in global active customers to 2.8 million.
- Launched Stelo OTC product, reaching 140,000 users in first 4 months, with plans for Amazon distribution and AI-driven personalization.
- Secured 2 of 3 largest PBMs covering DexCom CGM for type 2 non-insulin users, targeting 5 million U.S. lives by end-2025.
- France and New Zealand saw strong demand post-basal coverage wins, highlighting international growth potential.

**【CFO Financial Commentary】**
- Q4 2024 revenue: $1.11 billion (8% YoY growth), with U.S. revenue up 4% to $803 million.
- Gross profit: $661.2 million (59.4% margin), impacted by $21 million non-cash charge for inventory issues.
- Operating expenses: $451.7 million (10.6% YoY increase), driven by R&D and salesforce expansion.
- 2025 guidance: $4.6 billion revenue (14% YoY growth), 64-65% gross margin, 21% operating margin.
- Expect U.S. volume and revenue growth to converge in 2025, with 15-day G7 launch in H2 driving margin expansion.

**【Q&A Key Highlights】**
- **Salesforce productivity**: U.S. salesforce added 50,000 prescribers, with prescriptions per HCP rebounding despite channel mix shifts.
- **Type 2 non-insulin coverage**: 2 PBMs now cover DexCom CGM for 5 million U.S. lives, with RCT data expected late 2024 to support CMS expansion.
- **Stelo growth**: 2-3% of revenue in 2025, with Amazon launch and Oura integration enhancing engagement. Subscription renewal rates >90%.
- **15-day G7 sensor**: FDA approval expected soon, with Q4 2025 launch contingent on pump integrations and coverage wins.
- **International expansion**: France and New Zealand show strong post-rebate demand, with focus on type 2 intensive insulin markets.
- **Margins**: 200+ basis points of gross margin improvement in 2025 from G7 scale, with 15-day sensor contributing in 2026+.


DexCom (DXCM)-13 Feb 25-2024 Q4 Earnings call transcript

DexCom (DXCM)-24 Oct 24-2024 Q3 Earnings call transcript

Dexcom (DXCM)-25 Jul 24-2024 Q2 Earnings call transcript

Dexcom (DXCM)-25 Apr 24-2024 Q1 Earnings call transcript

Dexcom (DXCM)-8 Feb 24-2023 Q4 Earnings call transcript

- **Record Growth**: 26% organic revenue growth, driven by G7 adoption and Medicare expansion.
- **Market Leadership**: 18,000 new prescribers, 70% G7 customers new to DexCom, and 3M+ commercial coverage for basal users.
- **Profitability**: 24.5% operating margin and highest free cash flow quarter, enabling $500M buyback.
- **Future Drivers**: Non-insulin CGM launch 2024, Europe Basal coverage 2024, and direct Japan sales Q2 2024.
- **Share Repurchase**: $500M program to offset dilution, signaling confidence in stock value.


**【CEO Summary Section】**
- **Revenue Growth**: Q3 2023 organic revenue grew 26% YoY, driven by G7 launch success and Medicare expansion for basal insulin users.
- **G7 Adoption**: 18,000 new prescribers since launch, with 70% of G7 customers new to DexCom. Medicare new patient starts hit a record high.
- **International Expansion**: 30% organic growth in Europe, direct sales transition in Japan, and Dexcom ONE reimbursement secured in France for 0.5M people.
- **Product Innovation**: Non-insulin CGM product set to launch summer 2024, targeting type 2 diabetes patients not on insulin.
- **Clinical Evidence**: G7's accuracy and ease of use supported by 7M+ Medicare-eligible patients and 3M+ commercial coverage for basal users.

**【CFO Financial Commentary】**
- **Revenue**: $975M (27% YoY), with U.S. at $714M (+24%) and international at $261M (+33%).
- **Margins**: Gross margin 64.7%, operating margin 24.5% (new record), adjusted EBITDA 32.3%.
- **Free Cash Flow**: Q3 highest in company history, enabling $500M share buyback program.
- **Guidance Update**: Full year 2023 revenue raised to $3.575B-$3.6B (+23%-24%), with gross margin ~64%.

**【Q&A Key Highlights】**
- **Basal Contribution**: U.S. growth mirrors type 2 intensive insulin trajectory, with 40% adoption rate. Europe expected to follow 2024.
- **Non-Insulin Product**: 15-day CGM for type 2 patients, focusing on lifestyle insights. Payer conversations ongoing, launch summer 2024.
- **G7 Integration**: Pump firmware updates enable seamless transition from G6 to G7, no disruption expected in Q4.
- **Buyback Program**: $500M to offset convertible note dilution, reflecting confidence in long-term growth.
- **Japan Transition**: Spinning off non-CGM business to focus on CGM, with direct sales starting Q2 2024.


Actual											0.11	0.1975	0.235	0.2275	0.0825	0.19	0.2225	0.17	0.08	0.17	0.28	0.34	0.17	0.34	0.5	0.5	0.32	0.43	0.45	0.45	0.32	0.48	0.61	0.68
Forecast											0.0374	0.0842	0.1602	0.2321	0.0769	0.111	0.1623	0.2179	0.1308	0.1834	0.2445	0.2732	0.1461	0.2258	0.3407	0.4307	0.2696	0.3862	0.4345	0.4792	0.3272	0.4436	0.5763	0.6498
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+194.12%	+134.56%	+46.69%	-1.98%	+7.28%	+71.17%	+37.09%	-21.98%	-38.84%	-7.31%	+14.52%	+24.45%	+16.36%	+50.58%	+46.76%	+16.09%	+18.69%	+11.34%	+3.57%	-6.09%	-2.20%	+8.21%	+5.85%	+4.65%

DXCM

DXCM fundamentals

DXCM Q4 2025 Earnings

Earnings Call

You can ask Aime

DXCM

DXCM fundamentals

DXCM Q4 2025 Earnings

Earnings Call

DXCM Earnings Call Summary for Q4/20254:30 PM on Feb 12, 2026

DXCM Earnings Call Summary for Q3/20254:30 PM on Oct 30, 2025

DXCM Earnings Call Summary for Q2/20254:30 PM on Jul 30, 2025

DXCM Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

DXCM Earnings Call Summary for Q4/20244:30 PM on Feb 13, 2025

You can ask Aime